Advertisement

The European Commission has approved French drug maker Sanofi-aventis’ proposed acquisition of Genzyme Corp. The EU regulators said that they do not have anti-trust concerns because plenty of viable competitors exist in the therapeutic areas that the two companies are focused on.

A statement from the European Commission read in part:

SOURCE

Advertisement
Advertisement